Business Context and Reporting Period
This Form 8-K filing by Aileron Therapeutics, Inc. (ALRN) is dated June 1, 2020. The company is an emerging growth company focused on developing ALRN-6924, a chemoprotection agent designed to reduce chemotherapy-induced toxicity in patients with small cell lung cancer (SCLC).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and regulatory disclosures.
Material Changes and Clinical Results
The company announced positive interim data from the Phase 1b dose-optimization part of its ongoing Phase 1b/2 clinical trial of ALRN-6924 in patients with advanced, p53-mutated SCLC treated with topotecan.
- Study Population: 18 patients were enrolled across three dose levels (0.3, 0.6, and 1.2 mg/kg); 17 patients completed the first treatment cycle and were evaluable.
- Key Findings at 0.3 mg/kg: This dose level showed the lowest rate of NCI CTC Grade 3/4 hematological adverse events (17% anemia, 33% thrombocytopenia, 67% neutropenia). No patients at this dose required red blood cell or platelet transfusions.
- Comparison to All Doses: Across all dose levels, adverse event rates were higher (24% anemia, 35% thrombocytopenia, 88% neutropenia).
- Safety Profile: No patients across any dose level experienced febrile neutropenia or Grade 3/4 nausea, vomiting, diarrhea, or fatigue.
Guidance, Outlook, and Risks
Future Plans:
- The company is expanding the 0.3 mg/kg cohort from six to 14 patients.
- Enrollment in the schedule optimization part of the Phase 1b/2 trial is planned for June 2020.
- Top-line final data for dose and schedule optimization are expected in the fourth quarter of 2020.
- A Phase 2 randomized, placebo-controlled trial in second-line SCLC is targeted for initiation in Q1 2021, contingent on funding and prior results.
- Phase 1b trials in non-small cell lung cancer and an additional indication are targeted for Q2 2021.
Risks and Contingencies:
- Pandemic Impact: The company is monitoring the coronavirus pandemic, which may impact trial timing and data announcements.
- Funding: Future trial initiation is subject to obtaining sufficient funding.
- Forward-Looking Statements: Actual results may differ materially from expectations due to clinical trial outcomes, regulatory approvals, and cash resource sufficiency.
Investor Verification Checklist
- Verify the full interim data presentation filed as Exhibit 99.1 for detailed statistical analysis.
- Confirm the company's current cash runway and funding status to support the planned Q1 2021 Phase 2 trial.
- Monitor updates regarding the impact of the coronavirus pandemic on clinical site enrollment and operations.
- Track the timeline for the release of top-line final data expected in Q4 2020.